InMode Ltd. — Form 6-K Summary
Business Context and Reporting Period
InMode Ltd., an Israel-based medical technology company, furnished this Form 6-K for June 2020. The filing reports the results of the Special General Meeting of Shareholders held on June 16, 2020, and was dated June 19, 2020.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating and financial results.
Material Changes and Corporate Actions
- Shareholders approved the repricing of certain options granted to U.S. participants on November 25, 2019, and January 7, January 28, and February 17, 2020. The options were cancelled and re-granted with the same terms and vesting schedules, but with a reduced exercise price of $19.69.
- The approved repricing covered U.S. participant grants other than the executive-officer grants presented separately in Proposals 2, 3, and 4.
- Shareholders separately approved repricing of 90,000 options held by President—North America Shakil Lakhani, 20,000 options held by Chief Financial Officer Yair Malca, and 90,000 options held by Chief Medical Officer Dr. Spero Theodorou, all at a $19.69 exercise price.
Guidance, Risks, and Unusual Items
- The executive-officer option grants were approved on terms that exceeded limits in the Company’s compensation policy in effect at the time of the re-grants.
- The repricing had previously been approved by the Compensation Committee and Board on March 15, 2020 and was subsequently ratified by shareholders.
- The filing provides no management guidance, earnings outlook, litigation update, contingency estimate, or COVID-19 operating commentary.
Key Facts for Investors to Verify
- The total number of options covered by Proposal 1 is not specified in the filing text.
- Verify the complete terms, vesting schedules, expiration dates, and accounting treatment of the cancelled and re-granted options.
- Assess the dilution and potential compensation expense associated with the repriced options, including the 200,000 options granted to the three named executive officers.
- Review the Company’s proxy statement dated May 11, 2020 for voting results, additional grant details, and the compensation-policy exceptions.